The Pep Edit Newsletter

Notes from the desk

Latest research

Every note says what kind of study it was, what the drug’s status is, and what we still don’t know.

Quality

A COA can look official. Read it anyway.

HPLC purity is not “99% of this vial is peptide.” It is the relative purity of what was detected, not identity, sterility, or every contaminant.

A certificate of analysis is a lab report. It is not a seal of approval. The number people quote, usually a purity figure from HPLC, tells you how much of what the instrument detected matched the main peak. It does not tell you whether that peak is the peptide on the label, whether the vial is sterile, or whether anything the method cannot see is also in there.

Three questions do most of the work. Does the batch number on the certificate match the batch number on the vial? Is the testing lab named, and is it independent of the seller? Is there a second method, such as mass spectrometry, confirming identity rather than just purity?

None of this is a reason to buy anything. It is a reason to read the whole page before trusting a number that was designed to be screenshotted.

Women’s health

GLPs, menopause, and what we actually know

Hot flashes, mood, night sweats, weight changes. If a GLP is also in the picture, hormone therapy may change the landscape. The evidence is still early.

A question we get constantly: does hormone therapy change how the body responds to GLP-based medicines? Some early research has reported different weight-change outcomes in postmenopausal women who were also using hormone therapy. That is an interesting signal, and it is exactly the kind of signal that gets rounded up to a rule online.

What is missing is the boring part. The studies are small or observational, the populations are not the same, and the outcomes people care about (energy, sleep, mood, long-term health) are mostly not the outcomes being measured.

Our read: there is a real conversation here, it belongs between a woman and her clinician, and the honest answer today is “we do not know yet.” We will update this note when the evidence moves.

GLPs, menopause, and what we actually know card from The Pep Edit
Regulatory

How to read a compounding vote

When a committee votes, the useful post is the named list and the outcome, not a preview that the meeting exists.

Compounding news travels fast and loses detail on the way. A few peptides in our index have been discussed at FDA advisory committee meetings about which bulk substances compounding pharmacies may use. A committee vote is a recommendation. The FDA makes the final call, and the two can differ.

When you see a headline, look for four things: the name of the substance, the specific list or category being discussed, what the committee actually voted, and whether the agency has issued a final decision. A vote to recommend is not an approval, and a vote against is not a ban on research.

We keep the status stamp on every sheet deliberately plain for this reason. “Not FDA-approved” is a fact about a drug pathway, not a verdict on the science, and the science is what the sheet is for.

Leans on the KPV sheet.

How to read a compounding vote card from The Pep Edit

New notes, the day they publish.

One email a week. The study type named, every time.